2017 American Society of Clinical Oncology Annual Meeting*

In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.

In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.

Next-generation sequencing of circulating tumor DNA revealed complex mutational changes with panitumumab treatment.

Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.

No significant difference in OS noted, but patients in treated population who received SIRT experienced higher ORR and fewer AEs/serious AEs vs those who received sorafenib.

Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.

In this trial, adjuvant capecitabine improved survival vs placebo in patients with resected biliary cancer with modest toxicity and no reduction in quality of life.

Addition of PEGPH20 to nab-paclitaxel/gemcitabine improved PFS in the full study population with the greatest improvement in the patients with high tumor levels of hyaluronan.

AG-120 was associated with fatigue and gastrointestinal toxicities and prolonged stable disease.

In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.

Steven J. Cohen, MD Alan P. Venook, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 7, 2017 Expired: No longer available for credit

In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.